Psychiatry research · 2026
Acute and long-term psychiatric consequences of synthetic cannabinoids and related novel psychoactive substances: A systematic review.
СтатьяСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ricci Valerio, Chiappini Stefania, Martinotti Giovanni, Maina Giuseppe
Аннотация
BACKGROUND: Novel psychoactive substances (NPS) represent an evolving public health threat, yet evidence on their acute and long-term psychiatric consequences remains limited.
OBJECTIVE: To systematically review psychiatric and neurological consequences of NPS use across the full clinical spectrum, with primary focus on synthetic cannabinoids and related compounds, and to characterize differential risk patterns.
METHODS: Following PRISMA 2020 guidelines, we searched six databases (January 2005-August 2025). Primary inclusion required longitudinal studies with ≥6-month psychiatric follow-up; supplementary inclusion encompassed severe acute complications or fatalities to characterize the full toxicity spectrum and avoid survivor bias. We employed narrative synthesis with thematic analysis by substance class, focusing primarily on synthetic cannabinoids (n = 28 studies), synthetic cathinones (n = 12), and hallucinogens (n = 8, primarily NBOMe compounds).
RESULTS: Among 58 included studies, 28 (48.3 %) provided ≥6-month longitudinal follow-up, 22 (37.9 %) documented acute toxicity or fatalities, and 8 (13.8 %) mixed timeframes; 22 studies (37.9 %) were rated high quality. In one comparative cohort, hospitalizations for synthetic cannabinoid-related psychosis were markedly longer than for cannabis-related psychosis (43.45 vs. 22.91 days). In a case series, prolonged psychotic episodes beyond five months occurred in approximately 30 % of patients. Synthetic cathinone-related rhabdomyolysis rates reached 63 % in an outbreak series. NBOMe exposures were associated with fatality rates of approximately 15 % and Intensive Care admission rates of approximately 40 %.
CONCLUSIONS: Synthetic cannabinoids and related NPS may represent distinct toxicological class with enhanced psychiatric risks, potentially characterized by prolonged sequelae and severe neurological complications. Evidence suggests the need for clinical protocols, enhanced surveillance, and targeted prevention strategies.
OBJECTIVE: To systematically review psychiatric and neurological consequences of NPS use across the full clinical spectrum, with primary focus on synthetic cannabinoids and related compounds, and to characterize differential risk patterns.
METHODS: Following PRISMA 2020 guidelines, we searched six databases (January 2005-August 2025). Primary inclusion required longitudinal studies with ≥6-month psychiatric follow-up; supplementary inclusion encompassed severe acute complications or fatalities to characterize the full toxicity spectrum and avoid survivor bias. We employed narrative synthesis with thematic analysis by substance class, focusing primarily on synthetic cannabinoids (n = 28 studies), synthetic cathinones (n = 12), and hallucinogens (n = 8, primarily NBOMe compounds).
RESULTS: Among 58 included studies, 28 (48.3 %) provided ≥6-month longitudinal follow-up, 22 (37.9 %) documented acute toxicity or fatalities, and 8 (13.8 %) mixed timeframes; 22 studies (37.9 %) were rated high quality. In one comparative cohort, hospitalizations for synthetic cannabinoid-related psychosis were markedly longer than for cannabis-related psychosis (43.45 vs. 22.91 days). In a case series, prolonged psychotic episodes beyond five months occurred in approximately 30 % of patients. Synthetic cathinone-related rhabdomyolysis rates reached 63 % in an outbreak series. NBOMe exposures were associated with fatality rates of approximately 15 % and Intensive Care admission rates of approximately 40 %.
CONCLUSIONS: Synthetic cannabinoids and related NPS may represent distinct toxicological class with enhanced psychiatric risks, potentially characterized by prolonged sequelae and severe neurological complications. Evidence suggests the need for clinical protocols, enhanced surveillance, and targeted prevention strategies.